Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

1.

Development of targeted therapy in uterine serous carcinoma, a biologically aggressive variant of endometrial cancer.

El-Sahwi KS, Schwartz PE, Santin AD.

Expert Rev Anticancer Ther. 2012 Jan;12(1):41-9. doi: 10.1586/era.11.192. Review.

PMID:
22149431
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer.

Black JD, English DP, Roque DM, Santin AD.

Womens Health (Lond Engl). 2014 Jan;10(1):45-57. doi: 10.2217/whe.13.72. Review.

PMID:
24328598
[PubMed - indexed for MEDLINE]
3.

HER2/neu in Endometrial Cancer: A Promising Therapeutic Target With Diagnostic Challenges.

Buza N, Roque DM, Santin AD.

Arch Pathol Lab Med. 2014 Mar;138(3):343-50. doi: 10.5858/arpa.2012-0416-RA. Review.

PMID:
24576030
[PubMed - indexed for MEDLINE]
4.

Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer.

Santin AD, Bellone S, Siegel ER, Palmieri M, Thomas M, Cannon MJ, Kay HH, Roman JJ, Burnett A, Pecorelli S.

Am J Obstet Gynecol. 2005 Mar;192(3):813-8.

PMID:
15746676
[PubMed - indexed for MEDLINE]
5.

HER-2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications.

Villella JA, Cohen S, Smith DH, Hibshoosh H, Hershman D.

Int J Gynecol Cancer. 2006 Sep-Oct;16(5):1897-902.

PMID:
17009989
[PubMed - indexed for MEDLINE]
6.

Should all patients with serous and clear cell endometrial carcinoma receive adjuvant chemotherapy?

Boren TP, Miller DS.

Womens Health (Lond Engl). 2010 Nov;6(6):789-95. doi: 10.2217/whe.10.64.

PMID:
21118038
[PubMed - indexed for MEDLINE]
7.

Current treatment options for endometrial cancer.

Santin AD, Bellone S, O'Brien TJ, Pecorelli S, Cannon MJ, Roman JJ.

Expert Rev Anticancer Ther. 2004 Aug;4(4):679-89. Review.

PMID:
15270671
[PubMed - indexed for MEDLINE]
8.

HER2/neu gene amplification determines the sensitivity of uterine serous carcinoma cell lines to AZD8055, a novel dual mTORC1/2 inhibitor.

English DP, Roque DM, Carrara L, Lopez S, Bellone S, Cocco E, Bortolomai I, Schwartz PE, Rutherford T, Santin AD.

Gynecol Oncol. 2013 Dec;131(3):753-8. doi: 10.1016/j.ygyno.2013.08.033. Epub 2013 Sep 4.

PMID:
24012800
[PubMed - indexed for MEDLINE]
9.

Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: Hormonal therapy, chemotherapy and molecularly targeted therapies.

Gadducci A, Cosio S, Genazzani AR.

Crit Rev Oncol Hematol. 2006 Jun;58(3):242-56. Epub 2006 Jan 24. Review.

PMID:
16436330
[PubMed - indexed for MEDLINE]
10.

[Uterine papillary serous carcinoma--a different kind of tumor].

Steinman N, Avni A.

Harefuah. 1999 May 16;136(10):810-2. Review. Hebrew. No abstract available.

PMID:
10955120
[PubMed - indexed for MEDLINE]
11.

Histologic and immunohistochemical analyses of endometrial carcinomas: experiences from endometrial biopsies in 358 consultation cases.

Wei JJ, Paintal A, Keh P.

Arch Pathol Lab Med. 2013 Nov;137(11):1574-83. doi: 10.5858/arpa.2012-0445-OA.

PMID:
24168495
[PubMed - indexed for MEDLINE]
12.

Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases.

Yemelyanova A, Ji H, Shih IeM, Wang TL, Wu LS, Ronnett BM.

Am J Surg Pathol. 2009 Oct;33(10):1504-14. doi: 10.1097/PAS.0b013e3181ac35f5.

PMID:
19623034
[PubMed - indexed for MEDLINE]
13.

Systemic therapy in metastatic or recurrent endometrial cancer.

Pectasides D, Pectasides E, Economopoulos T.

Cancer Treat Rev. 2007 Apr;33(2):177-90. Epub 2006 Dec 29. Review.

PMID:
17196749
[PubMed - indexed for MEDLINE]
14.

HMGA2 is commonly expressed in uterine serous carcinomas and is a useful adjunct to diagnosis.

McCluggage WG, Connolly LE, McBride HA, Kalloger S, Gilks CB.

Histopathology. 2012 Mar;60(4):547-53. doi: 10.1111/j.1365-2559.2011.04105.x. Epub 2012 Jan 17.

PMID:
22250726
[PubMed - indexed for MEDLINE]
15.

The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma.

Zheng W, Yi X, Fadare O, Liang SX, Martel M, Schwartz PE, Jiang Z.

Am J Surg Pathol. 2008 Feb;32(2):304-15. doi: 10.1097/PAS.0b013e3181483ff8.

PMID:
18223334
[PubMed - indexed for MEDLINE]
16.

Antiangiogenic agents in advanced, persistent or recurrent endometrial cancer: a novel treatment option.

Gadducci A, Sergiampietri C, Guiggi I.

Gynecol Endocrinol. 2013 Sep;29(9):811-6. doi: 10.3109/09513590.2013.801446. Epub 2013 Jun 14. Review.

PMID:
23767831
[PubMed - indexed for MEDLINE]
17.

Higher sensitivity to patupilone versus paclitaxel chemotherapy in primary uterine serous papillary carcinoma cell lines with high versus low HER-2/neu expression in vitro.

Paik D, Cocco E, Bellone S, Casagrande F, Bellone M, Siegel EE, Richter CE, Schwartz PE, Rutherford TJ, Santin AD.

Gynecol Oncol. 2010 Oct;119(1):140-5. doi: 10.1016/j.ygyno.2010.06.024. Epub 2010 Jul 31.

PMID:
20673976
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses.

Kuhn E, Wu RC, Guan B, Wu G, Zhang J, Wang Y, Song L, Yuan X, Wei L, Roden RB, Kuo KT, Nakayama K, Clarke B, Shaw P, Olvera N, Kurman RJ, Levine DA, Wang TL, Shih IeM.

J Natl Cancer Inst. 2012 Oct 3;104(19):1503-13. doi: 10.1093/jnci/djs345. Epub 2012 Aug 23.

PMID:
22923510
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Recurrence patterns and prognosis of endometrial stromal sarcoma and the potential of tyrosine kinase-inhibiting therapy.

Cheng X, Yang G, Schmeler KM, Coleman RL, Tu X, Liu J, Kavanagh JJ.

Gynecol Oncol. 2011 May 1;121(2):323-7. doi: 10.1016/j.ygyno.2010.12.360. Epub 2011 Jan 28.

PMID:
21277011
[PubMed - indexed for MEDLINE]
20.

Papillary serous carcinoma of the peritoneum coexisting with or after endometrial carcinoma.

Altaras MM, Bernheim J, Zehavi T, Drucker L, Uziel O, Fishman A.

Gynecol Oncol. 2002 Feb;84(2):245-51. Erratum in: Gynecol Oncol 2002 Mar;84(3):540.

PMID:
11812082
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk